The role of mechanical circulatory support as destination therapy for ambulatory heart failure

Authors

  • James K Kirklin Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA

DOI:

https://doi.org/10.21542/gcsp.2016.24

Abstract

Continuous flow technology has dramatically improved patient survival during ventricular assist device (VAD) therapy in recent years. Health-related quality of life is improved by at least two years. Despite remarkable progress in this field, major adverse events during VAD support limit the effectiveness of this therapy and present major barriers to its extension to ambulatory advanced heart failure patients. The pace of progress will depend on improvements in both the adverse event profile and development of semi-quantitative methodology to calculate and display a composite of survival and health-related quality of life. 

Downloads

Published

2016-12-07

Issue

Vol. 2016 No. 3 (2016)

Section

Review articles

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.